Dengue Alliance

Developing affordable and accessible treatments for dengue through partnerships with institutions in the most affected countries

Founded: 2022

A global partnership led by institutions from dengue-endemic countries, the Dengue Alliance is advancing urgently needed pre-clinical research, testing the efficacy of repurposed drug candidates, and implementing clinical trials of the most promising potential dengue treatments. Alliance members also coordinate efforts to help overcome knowledge gaps, expedite clinical research and regulatory review, address unmet needs in diagnostics, mobilize resources, and share research knowledge openly.

Dengue, a climate-sensitive neglected tropical disease, is one of the top ten threats to global public health worldwide. Despite an estimated 390 million infections each year in more than 100 countries, there is no specific treatment available. More than 70% of the disease burden is estimated to be in Asia, with rapidly growing incidence in other parts of the world – in particular the Americas.

Alliance updates

2023

3 laboratories upgraded (Senegal, Democratic Republic of the Congo, and Ghana).
13 people trained for clinical trials.
Held two expert meetings to discuss clinical trial design for dengue.
Participated in ASTMH and ECTMIH conferences.
Published two journal articles on the Alliance’s ongoing dengue seroprevalence study.
Progressed pre-clinical profiling of existing direct-acting antiviral compounds and host-directed therapies.

2022

Held an expert consultation on laboratory testing in dengue seroprevalence studies with 26 participants representing 12 countries and 10 institutions.
Completed pre-clinical profiling of three direct-acting antiviral compounds for their potential to inhibit the dengue virus.
Prepared and submitted protocols for a dengue seroprevalence study.
Concluded collaboration agreements with six research institutions in the Dengue Alliance.